![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png){kind=small}
symbioidljPsilocybin in the Treatment of Obsessive-Compulsive Disorder
Investigator: Pedro Delgado, MD and Francisco Moreno, MD
University of Arizona, Tucson, USA
E-mail: delgado@u.arizona.edu
Sponsor: Heffter/MAPS
This is the first FDA-approved study in more than 25 years to examine the use of psilocybin in a patient population. The principal investigators plan to study the use of psilocybin in 10 patients suffering from obsessive-compulsive disorder (OCD). They want to determine if they can replicate in a clinical study several published case reports of patients whose OCD symptoms were reduced after self- experimentation with psilocybin mushrooms. The study is close to being initiated. MAPS has paid $12,000 for the synthesis of one gram of psilocybin. Analytical data on this psilocybin has been submitted to FDA in March, 2001, with approval obtained from the FDA on May 9, 2001. DEA licenses received July 2, 2001. Patient recruitment is now underway.
-------------
VERY Interesting indeed. This was found from the maps website... www.maps.org
Investigator: Pedro Delgado, MD and Francisco Moreno, MD
University of Arizona, Tucson, USA
E-mail: delgado@u.arizona.edu
Sponsor: Heffter/MAPS
This is the first FDA-approved study in more than 25 years to examine the use of psilocybin in a patient population. The principal investigators plan to study the use of psilocybin in 10 patients suffering from obsessive-compulsive disorder (OCD). They want to determine if they can replicate in a clinical study several published case reports of patients whose OCD symptoms were reduced after self- experimentation with psilocybin mushrooms. The study is close to being initiated. MAPS has paid $12,000 for the synthesis of one gram of psilocybin. Analytical data on this psilocybin has been submitted to FDA in March, 2001, with approval obtained from the FDA on May 9, 2001. DEA licenses received July 2, 2001. Patient recruitment is now underway.
-------------
VERY Interesting indeed. This was found from the maps website... www.maps.org
![[identity profile]](https://www.dreamwidth.org/img/silk/identity/openid.png){kind=small}
no subject
Date: 2001-07-11 07:37 pm (UTC)with the more monomanical attributes of ocd, i would think that in some cases the psilocyin would act as a reinforcement for the individuals personalized dillusions, since i think that ocd is primarily a form of fear manifested, and the compulsive activity is a way to deal with, and control the outside world.
or possibly show them the narrowness of this fear and worldview.
should be interesting to see how it unfolds, regardless.
Re:
Date: 2001-07-11 10:05 pm (UTC)Re:
Date: 2001-07-12 12:16 pm (UTC)no subject
Date: 2001-07-11 07:52 pm (UTC)Re:
Date: 2001-07-11 09:46 pm (UTC)no subject
Date: 2001-07-12 05:51 am (UTC)